Synlogic presents additional preclinical data on therapeutic candidates synb1934 for phenylketonuria (pku) and synb8802 for enteric hyperoxaluria at synthetic biology: engineering, evolution & design (seed) conference

Cambridge, mass., june 15, 2021 /prnewswire/ -- synlogic, inc. (nasdaq: sybx), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented on the development of the investigational synthetic biotic medicine™ synb8802 for the treatment of enteric hyperoxaluria and on synb1934, an evolved strain of synthetic biotic medicine synb1618, for the treatment of phenylketonuria (pku) during the synthetic biology: engineering, evolution & design (seed) conference, being held virtually june 15-18, 2021.
SYBX Ratings Summary
SYBX Quant Ranking